Literature DB >> 28778432

Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease.

Kiah McCabe1, Ruth M Concannon1, Declan P McKernan2, Eilís Dowd1.   

Abstract

Because Toll-like receptors (TLRs) are emerging as potential targets for anti-inflammatory intervention in neurodegenerative diseases, the aim of this study was to characterise the time-course of TLR expression in neurotoxic, environmental and inflammatory Parkinson's disease models. Male Sprague Dawley rats were given intra-striatal injections of 6-hydroxydopamine (10μg), rotenone (1.25μg), LPS (10μg) or Poly I:C (20μg) and were sacrificed on Days 1, 4, 14 and 28 post surgery. Changes in the expression of several inflammatory markers, including TLR3, TLR4 and selected cytokines, were examined using qRT-PCR. We found pronounced changes in the bacterial responsive TLR4 and the viral responsive TLR3 receptors in the inflamed striatum in all models, regardless of whether the challenge was neurotoxic, environmental or inflammatory in nature. However, the magnitude and time-course of changes in expression was different between the different models. This study highlights the pattern of changes in TLR expression in models of Parkinson's disease, and further strengthens the rationale for targeting TLRs for anti-inflammatory intervention in this neurodegenerative disease.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6-OHDA; Animal models; Cytokines; LPS; Neuroinflammation; Parkinson's disease; Poly I:C; Rotenone; Toll-like-receptors

Mesh:

Substances:

Year:  2017        PMID: 28778432     DOI: 10.1016/j.jneuroim.2017.07.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients.

Authors:  Zhang Ping; Wu Xiaomu; Xie Xufang; Shao Liang
Journal:  Neurol Sci       Date:  2018-10-12       Impact factor: 3.307

Review 2.  The role of Toll-like receptors and neuroinflammation in Parkinson's disease.

Authors:  Arash Heidari; Niloufar Yazdanpanah; Nima Rezaei
Journal:  J Neuroinflammation       Date:  2022-06-06       Impact factor: 9.587

Review 3.  Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug?

Authors:  Rohit Kumar Tiwari; Afrasim Moin; Syed Mohd Danish Rizvi; Syed Monowar Alam Shahid; Preeti Bajpai
Journal:  Metab Brain Dis       Date:  2021-03-11       Impact factor: 3.584

4.  The expression and significance of tyrosine hydroxylase in the brain tissue of Parkinsons disease rats.

Authors:  Yuan Chen; Yajun Lian; Yunqing Ma; Chuanjie Wu; Yake Zheng; Nanchang Xie
Journal:  Exp Ther Med       Date:  2017-09-18       Impact factor: 2.447

Review 5.  A role for viral infections in Parkinson's etiology?

Authors:  Laura K Olsen; Eilis Dowd; Declan P McKernan
Journal:  Neuronal Signal       Date:  2018-04-16

6.  Back to the future: lessons from past viral infections and the link with Parkinson's disease.

Authors:  Eilis Dowd; Declan P McKernan
Journal:  Neuronal Signal       Date:  2021-04-16

Review 7.  TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut.

Authors:  Anastazja M Gorecki; Chidozie C Anyaegbu; Ryan S Anderton
Journal:  Transl Neurodegener       Date:  2021-11-17       Impact factor: 8.014

Review 8.  Supramolecular organizing centers at the interface of inflammation and neurodegeneration.

Authors:  Petra Sušjan-Leite; Taja Železnik Ramuta; Elvira Boršić; Sara Orehek; Iva Hafner-Bratkovič
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

Review 9.  The Effect of Aggregated Alpha Synuclein on Synaptic and Axonal Proteins in Parkinson's Disease-A Systematic Review.

Authors:  Jennifer Murphy; Declan P McKernan
Journal:  Biomolecules       Date:  2022-08-29

Review 10.  Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease.

Authors:  Rachel Kelly; Valerie Joers; Malú G Tansey; Declan P McKernan; Eilís Dowd
Journal:  Molecules       Date:  2020-01-21       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.